Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Journal of Experimental & Clinical Cancer Research

Yang Qu²  Lailong Luo³  Fei Fei³  Li Li³  Zhe Rong¹ 

[1] Department of Basic Medicine & Experimental Technology, Division of Clinical Medicine, Logistic University of Chinese People’s Armed Police Force, Tianjin 300162, P. R. China;Department of Neurosurgery, Logistic University Affiliated Hospital, Logistic University of Chinese People’s Armed Police Force, Tianjin 300162, P. R. China;Department of Pathology, Anhui Medical University, Hefei, Anhui Province 230032, P. R. China

关键词: Matrix metalloproteinase;    Breast cancer;    Tientsin Albino 2;    CoCl₂;    Glibenclamide;   

Others  :  825037
DOI  :  10.1186/1756-9966-32-32

 received in 2013-04-25, accepted in 2013-05-26,  发布年份 2013

【 摘 要 】

Background

To observe the influence of combination treatment with glibenclamide and CoCl₂ on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9.

Methods

50 adult female TA2 mice were randomly divided into 5 groups including DMSO control, CoCl_2, glibenclamide, CoCl₂ + glibenclamide and paclitaxel. All of these mice were inoculated with TA2 spontaneous breast cancer cells in the left groin. Nine days after inoculation the tumor could be palpated. Different treatments for each group were then subcutaneously administered near the tumors on the 9th and 14th days after injection. Tumor size was measured to determine the growth curve. All mice were sacrificed on the 18th day after initial inoculation and tumor tissues were collected. Some fresh tissues without necrosis were stored at −80°C for mRNA detection and the other tumor tissue was fixed with 10% formalin for H&E and immunohistochemical staining.

Results

The growth rate of tumor cells in the CoCl₂ + glibenclamide group was lower than that seen in the other groups. On the 14th day, the average volume of tumor in the CoCl₂ + glibenclamide group was the lowest and the difference has statistical significance (P < 0.05), while the differences among the CoCl₂, glibenclamide and paclitaxel had no statistical significance. The mean percentage of cells expressing MMP9 and PCNA was the lowest in the CoCl₂ + glibenclamide group (P < 0.05). MMP9 mRNA expression paralleled MMP9 protein expression in these groups (P < 0.05).

Conclusions

Combined treatment with glibenclamide and CoCl₂ inhibits TA2 spontaneous breast cancer growth and invasiveness with effects similar to paclitaxel.

【 授权许可】

   
2013 Rong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kaufmann M, Rody A: Long-term risko f breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005, 131:487-494.
• [2]Sun B, Zhang S, Zhang D, Liu Y, Li Y, Rong Z, Zhu Y, Jia X: Clusterin is associated with spontaneous breast cancer in TA2 mice. FEBS Lett 2007, 581(17):3277-3282.
• [3]Robert V, Hideaki N: Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circul Res 2003, 92(8):827-839.
• [4]Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Clin Invest 2004, 114(5):623-633.
• [5]Park KS, Kim SJ, Kim KH, Kim JC: Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 2011, 26(2):391-397.
• [6]Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O: The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers. PLoS One 2013, 8(1):e54251.
• [7]Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47.
• [8]Piret JP, Mottet D, Raes M, Michiels C: CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann N Y Acad Sci 2002, 973:443-447.
• [9]Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J: Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 2013., 96[Epub ahead of print]
• [10]Marble A: Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Drugs 1971, 1(2):109-115.
• [11]Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, Gerzanich V: Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006, 12(4):433-440.
• [12]Riddle MC: Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide? J Clin Endocrinol Metabol 2003, 88(2):528-530.
• [13]Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC Jr, Liu J: Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett 2012, 326(2):176-182.
• [14]Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB: Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62(4):1087-1092.
• [15]Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW, Yang HO: Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 2004, 91(5):1043-1052.
• [16]Marshall SF, Clarke CA, Deapen D, Henderson K, Largent J, Neuhausen SL, Reynolds P, Ursin G, Horn-Ross PL, Stram DO, Templeman C, Bernstein L: Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010, 12(1):R4. BioMed Central Full Text
• [17]Yang L, Li LD, Chen YD, Parkin DM: Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi 2006, 28(6):438-440.
• [18]Shin HR, Joubert C, Boniol M, Hery C, Ahn SH, Won YJ, Nishino Y, Sobue T, Chen CJ, You SL, Mirasol-Lumague MR, Law SC, Mang O, Xiang YB, Chia KS, Rattanamongkolgul S, Chen JG, Curado MP, Autier P: Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 2010, 21(11):1777-1785.
• [19]Wong IO, Cowling BJ, Schooling CM, Leung GM: Age-period-cohort projections of breast cancer incidence in a rapidly transitioning Chinese population. Int J Cancer 2007, 121(7):1556-1563.
• [20]Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC: Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 2013, 105(2):104-112.
• [21]Yin Y, Yang Z, Zhang S: Combined treatment with exogenous estradiol and progesterone increases the incidence of breast cancer in TA2 mice without ovaries. Cancer Lett 2011, 311(2):171-176.
• [22]Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y: Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008, 14(21):7050-7059.
• [23]Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X: Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007, 249(2):188-197.
• [24]Zhang S, Li M, Zhang D, Xu S, Wang X, Liu Z, Zhao X, Sun B: Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Invest 2009, 89(5):575-586.
• [25]Pilati P, Mocellin S, Miotto D, Fitta C, Casara D, Ori C, Scalerta R, Nitti D, Lise M, Rossi CR: Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. Oncol Rep 2004, 12:895-901.
• [26]Guadagni S, Santinami M, Patuzzo R, Pilati PL, Miotto D, Deraco M, Rossi CR, Fiorentini G, Di Filippo F, Valenti M, Amicucci G: Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res 2003, 13:51-58.
• [27]Ho VT, Bunn HF: Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Biochem Biophys Res Commun 1996, 223(1):175-180.
• [28]Groop LC: Sulphonylureas in NIDDM. Diabetes Care 1992, 15(6):737-754.
• [29]Pardo LA: Voltage-gated potassium channels in cell proliferation. Physiology 2004, 19:285-292.
• [30]Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS: Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane release in HepG2 human hepatoblastoma cells. Biochem Biophys Res Commun 1999, 261:682-688.
• [31]Qian X, Li J, Ding J, Wang Z, Duan L, Hu G: Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol 2008, 76:1705-1715.
• [32]Núñez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E, Bergoc R, Martín G: Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol 2013, 14:6. BioMed Central Full Text
• [33]Kijima T, Kinukawa N, Gooding WE, Uno M: Association of Epstein-Barr virus with tumor cell proliferation: clinical implication in nasopharyngeal carcinoma. Int J Oncol 2001, 18(3):479-485.
• [34]Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H, Sabo E: Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002, 41(6):519-525.
• [35]Saadoun D, Bieche I, Authier FJ, Laurendeau I, Jambou F, Piette JC, Vidaud M, Maisonobe T, Cacoub P: Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2007, 56(4):1315-1324.
• [36]Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer Causes Control 2000, 89(4):715-723.
• [37]Dean RA, Overall CM: Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 2007, 6(4):611-623.
• [38]Seyfried TN, Shelton LM: Cancer as a metabolic disease. Nutr Metab (Lond) 2010, 7:7. BioMed Central Full Text